ImmuCell Corporation THIRD AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENTIncentive Compensation Agreement • November 21st, 2022 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Third Amended and Restated Incentive Compensation Agreement, dated as of November 11, 2022, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Elizabeth L. Williams (the “Executive”), and replaces and supersedes in its entirety the Second Amended and Restated Incentive Compensation Agreement, dated as of March 28, 2022, between the Company and the Executive.
